Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Apr 2025, 18:43.
PERCEPTIVE ADVISORS LLC - 03 Apr 2025 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ALDX
- Reported as of
- 03 Apr 2025
- Net transaction value
- -$4,828,000
- SEC form
- 4
- Accepted by SEC
- 07 Apr 2025, 18:43:07 UTC
- Prior SEC filing
- 21 Feb 2025
- Next SEC filing
- 29 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 07 Apr 2025.
Change
- Previous filing in this sequence was filed on 21 Feb 2025.
- Current net transaction value: -$4,828,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALDX
transaction
Common Stock
Sale
- Transaction value
- $4,828,000
- Shares
- -3,400,000
- Change %
- -37%
- Price
- $1.42
- Shares after
- 5,875,851
- Date
- 03 Apr 2025
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
PERCEPTIVE ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.78 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Footnote F2
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.